Artiva Biotherapeutics, Inc.(ARTV) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights IND clearance and initiation of global basket trial exploring AlloNK® + rituximab in refractory rheumatoid arthritis, Sjögren's disease, idiopathic inflammatory myopathies and systemic sclerosis First trial to explore an allogeneic cell therapy in refractory rheumatoid arthritis and Sjögren's disease in the U.S. Initial safety, translational data, and lead indication selection to be presented by year ...